Democrats have wanted to let Medicare negotiate drug prices for decades, and this week might bring details on how the government would enforce price negotiation, whether biosimilars would be protected from negotiation and the extent to which insulin would be singled out for price and cost controls in the budget reconciliation bill. However, the fate of Medicare drug price negotiation still relies on whether Sen. Kyrsten Sinema (D-AZ) goes along with tax increases, unrelated to health care, that were added...